Results 161 to 170 of about 21,018 (198)

Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia. [PDF]

Blood Adv
Ramassone A, Pagotto S, Di Marco M, Rashid MM, Di Camillo C, Palmiero F, Innocenti I, Autore F, Tomasso A, Laurenti L, Visone R.   +10 more
europepmc   +1 more source

Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ibrahim EIK, Friberg LE.
europepmc   +1 more source

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. [PDF]

Lancet
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators.   +30 more
europepmc   +1 more source

From Treatment to Perturbation: Interpreting the ON–OFF Ibrutinib Trial as a Dynamic Clinical Experiment

Anita Domargård
openalex   +1 more source

Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL). [PDF]

Cancer Med
Krackeler ML, Chee BH, Orchanian AK, Liu R, Law L, Zhu S, Zhu Z, Sakoda LC, Buchanan S, Massoudi M, Lopez A, Tavakoli J.   +11 more
europepmc   +1 more source

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial. [PDF]

Leukemia
Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Giné E, Visco C, Brüggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C, European MCL Network.   +28 more
europepmc   +1 more source

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL. [PDF]

Blood Adv
Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, Besikli-Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer-Lores B, Garcia Vela JA, Gentile M, Vázquez EG, Gutwein O, Herishanu Y, Jablonowska-Babij P, Jaksic O, Josefsson P, Kalicińska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Mela Osorio MJ, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Savaş EM, Scarfò L, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtzi P, Tranidou A, Visentin A, Vrachiolias G, Wasik-Szczepanek E, Wróbel T, Yağcı M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren-Michowitz M.   +56 more
europepmc   +1 more source

Uncovering regulatory B-cell features associated with regulatory T-cell expansion and global T-cell exhaustion in Waldenström macroglobulinemia <i>Myd88</i> ^<i>L252P</i> -like lymphoplasmacytic lymphomas. [PDF]

Hemasphere
Lemasson Q, Tabaud M, Téteau O, Carle B, Chabaud M, Feuillard J, Faumont N, Vincent-Fabert C.   +7 more
europepmc   +1 more source

Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report. [PDF]

Front Oncol
Lv Z, Lu P, Jing C, Yi X, Wu X.
europepmc   +1 more source